Autobahn Therapeutics: $100 Million Raised To Develop Restorative Treatments For Depression and Other CNS Disorders
By Amit Chowdhry ● Jul 28, 2024
Autobahn Therapeutics (a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders) announced the closing of an oversubscribed $100 million Series C funding led by Newpath Partners, with participation from new investors Canaan Partners, Monograph Capital, and Insight Partners. All of the company’s existing investors participated in the round, including founding investors ARCH Venture Partners and Blue Owl Healthcare Opportunities, BVF Partners, Invus, Samsara BioCapital, Biogen, Bristol Myers Squibb, Pfizer Ventures, Section 32, Alexandria Venture Investments and GT Healthcare Capital Partners.